Business Context and Reporting Period
This Form 8-K was filed by AIT Therapeutics, Inc. on June 13, 2018. The registrant is an emerging growth company incorporated in Delaware. The filing reports on financial results for the three months ended March 31, 2018, and announces clinical trial data released on June 13, 2018.
Key Financial Metrics
The filing references a press release (Exhibit 99.1) containing the full financial results for the three months ended March 31, 2018. However, the text of this Form 8-K does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Developments
- Clinical Trial Results: On June 13, 2018, the Company announced top-line data from its Nitric Oxide in Bronchiolitis (NO-BRO) Pilot Study in infants.
- Key Outcome: The study demonstrated a reduction in hospital length-of-stay of 21 hours.
- Financial Reporting: Financial results for the quarter ended March 31, 2018, were announced on June 14, 2018, but specific comparative metrics versus prior periods are not detailed in this summary text.
Guidance, Outlook, and Risks
The filing does not contain explicit forward-looking guidance, management commentary on future financial performance, or a detailed risk factor section within the body text. The document notes that the information contained herein, including the press releases, is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, limiting liability for the statements made.
Investor Verification Checklist
- Review Exhibit 99.1 for specific revenue, net loss, and cash position figures for the quarter ended March 31, 2018.
- Examine Exhibit 99.2 for detailed methodology and statistical significance of the NO-BRO Pilot Study results.
- Verify the Company's cash runway and funding status given the lack of specific liquidity data in this filing.
- Confirm the regulatory pathway and next steps for the Nitric Oxide therapy following the pilot study announcement.